P16 protein abnormality in Epstein-Barr virus-associated gastric carcinomas

Anticancer Res. 2006 Mar-Apr;26(2A):933-7.

Abstract

Background: The Epstein-Barr virus (EBV) has been detected in lymphoepithelioma of the nasopharynx and lymphoepithelioma-like carcinomas in various organs. Ten percent of gastric carcinomas, including lymphepithelioma-like carcinoma and adenocarcinoma, are associated with EBV infection. The p16 protein is a cyclin-dependent kinase (CDK) inhibitor that decelerates the cell cycle, inactivating the CDKs that phosphorylate retinoblastoma (Rb) protein.

Materials and methods: To clarify the relationship between p16 overexpression and EBV-associated gastric carcinomas, immunohistochemical analysis of p16 and detection of EBV by in situ hybridization were performed on 238 formalin-fixed and paraffin-embedded samples of gastric carcinomas.

Results: The non-expression of p16 protein in EBV-positive and -negative carcinoma was 81.5% (53 out of 65 samples) and 26.6% (46 out of 173 samples), respectively (p < 0.001).

Conclusion: We suggest that the carcinogenesis of EBV-associated gastric cancers may be closely associated with a p16 abnormality.

MeSH terms

  • Adenocarcinoma / genetics
  • Adenocarcinoma / metabolism*
  • Adenocarcinoma / pathology
  • Adenocarcinoma / virology*
  • Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis*
  • Epstein-Barr Virus Infections / complications*
  • Epstein-Barr Virus Infections / genetics
  • Epstein-Barr Virus Infections / metabolism*
  • Female
  • Genes, p16 / physiology
  • Herpesvirus 4, Human / genetics
  • Humans
  • Immunohistochemistry
  • In Situ Hybridization
  • Male
  • Middle Aged
  • Stomach Neoplasms / genetics
  • Stomach Neoplasms / metabolism*
  • Stomach Neoplasms / pathology
  • Stomach Neoplasms / virology*

Substances

  • Cyclin-Dependent Kinase Inhibitor p16